(Q80098730)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16904446%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

title

Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16904446%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference

3

Roger Dmochowski

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16904446%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1

Steven A Kaplan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16904446%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

2

Claus G Roehrborn

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16904446%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

author name string

Eric S Rovner

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16904446%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Joseph T Wang

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16904446%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Zhonghong Guan

series ordinal

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16904446%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

language of work or name

English

0 references

publication date

1 August 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16904446%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16904446%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

volume

68

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16904446%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16904446%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

page(s)

328-332

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16904446%20AND%20SRC:MED&resulttype=core&format=json

The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.

28 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.006

Prevalence and burden of overactive bladder in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.006

How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.006

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.006

Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.006

Videourodynamic studies in men with lower urinary tract symptoms: a comparison of community based versus referral urological practices

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.006

The effect of bladder outflow obstruction on detrusor blood flow changes during the voiding cycle in conscious pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.006

Bladder instability and denervation in patients with bladder outflow obstruction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.006

Correlation between detrusor collagen content and urinary symptoms in patients with prostatic obstruction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.006

Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.006

Symptoms and urodynamics after unsuccessful transurethral prostatectomy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.006

Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.006

Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.006

Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.006

Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.006

Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.006

Costs of urinary incontinence and overactive bladder in the United States: a comparative study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.006

The wet patient: understanding patients with overactive bladder and incontinence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.006

A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.006

Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.006

Evidence for the efficacy and safety of tolterodine in the treatment of overactive bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.006

Clinical efficacy and tolerability of extended‐release tolterodine and immediate‐release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo‐controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.006

10.1016/J.UROLOGY.2006.03.006

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16904446%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference